Dr Yoshimitsu Soga (Kokura Memorial Hospital, Fukuoka, JP) discusses drug-coated balloon (DCB) outcomes in the femoropopliteal by vessel size.

 

Questions:

1. What insight does this data offer?

2. What was the design of the study and which patients were eligible?

3. How should this data influence clinical practice?

4. What research should be conducted in follow up to this study?

 

Filmed on location at the Leipzig Interventional Course 2020. 

 

Interviewer: Ashlynne Merrifield

Videographer: Natascha Wienand

 

Transcript Below : 

Question 1 :  What insight does this data offer?

DCB is very effective, but, so, in each vessel size, the primary patency remains unclear. Therefore today we offer the data in each vessel size data. 

Question 2 : What was the design of the study and which patients were eligible?

This data is a pooled data, the global cohort of IN.PACT, so we enrolled much more patient data. This study encouraging many countries cohort data, then we analyse it in each vessel size. 

Question 3 : How should this data influence clinical practice?

So, our data suggested that, so, IN.PACT DCB is very useful for in each vessel size, so generally speaking the smaller the worse, the bigger the better. However if we could use the drug coated balloon so even even for the smaller vessels we can, it's treatable. So, in Asian people, the very small, the tiny vessel, is common. Therefore, so, risk analysis rate is pretty high, however, so we overcome the primary patency improving, by using the IN.PACT Admiral. 

Question 4 : What research should be conducted in follow up to this study?

Well, today I presented just one year's result in each vessel size. Therefore the longer term result, the longer term safety composite endpoint is needed.